7 results about "Cell-mediated cytotoxicity" patented technology

Methods for treating T cells with venetoc to enhance T cell-mediated cytotoxicity and / or T cell-mediated antitumor activity are described. Enhanced T cell populations and their related methods and uses in cancer treatment are also described.

The invention discloses a bispecific fully humanized single-domain antibody targeting a novel coronavirus and CD16a and an application of the bispecific fully humanized single-domain antibody. The antibody comprises a single-domain antibody n3130v targeting a novel coronavirus and a single-domain antibody n118 targeting a human CD16a, the amino acid sequence of the n3130v is as shown in SEQ ID NO: 1, and the amino acid sequence of the n118 is as shown in SEQ ID NO: 2. The antibody disclosed by the invention has the capabilities of broad-spectrum recognition and neutralization of novel coronavirus, can be efficiently combined with a CD16a target spot, and is used for mediating antibody-dependent cell-mediated cytotoxic action (ADCC). The bispecific antibody can be used for novel coronavirus related research and treatment of diseases caused by novel coronavirus infection.

Compositions and methods for treating general persistent viral infections, particularly long COVID, are described. The compositions comprise T cells, antigen presenting cells (APCs), and optionally NK cells derived from a patient's whole blood. The APCs are genetically engineered to comprise nucleic acids encoding antigenic peptide sequences for MHC-complexed cell surface expression, where further exposure to an IL-15 agonist and patient T cells can produce activation and expansion of virus-educated T cells for readministration to the patient, thereby targeting cells harboring the virus to T cell-mediated cytotoxicity.

This disclosure pertains to a nucleic acid encoding a fusion protein that specifically targets CD300A. It also provides pluralities of nucleic acids that further comprise a chimeric receptor-encoding nucleic acid, such as a nucleic acid encoding a NK-targeting CAR. Vectors, compositions, engineered cells, and populations of cells containing such nucleic acids are also provided herein. Uses of these fusion proteins, nucleic acids, vectors, engineered cells, or populations of engineered cells in promoting resistance to NK cell-mediated cytotoxicity in an allogeneic setting, preventing or treating transplant rejection, and preventing or treating diseases, such as cancers or autoimmune diseases, are also provided herein.

Described herein are bispecific antibodies simultaneously targeting both CHI3L1 and the immune checkpoint molecule PD-1. These antibodies manifest enhanced synergistic cytotoxic effects compared to the effects of individual CHI3L1 and PD-1 antibodies, alone or in combination. Methods of treating a cancer by administering the bispecific antibodies described herein are also provided.

This invention provides a pharmaceutical composition for treating cancer through effective immunotherapy against immune checkpoint inhibitor molecules. [Solution] A bispecific antibody is provided that detects and neutralizes CHI3L1 and PD-1, comprising an antigen-binding moiety of an anti-human programmed death receptor 1 (PD-1) antibody and an antigen-binding moiety of an anti-human chitinase 3-like-1 (CHI3L1) antibody.

To provide more effective immunotherapy against individual immune checkpoint inhibitor molecules such as PD-1.SOLUTION: The present invention provides a humanized bispecific antibody that simultaneously detects and neutralizes both CHI3L1 and the immune checkpoint inhibitor PD-1, wherein these antibodies exhibit enhanced synergistic cytotoxic effects compared to the effects of individual CHI3L1 and PD-1 antibodies, alone or in combination. A pharmaceutical composition comprising the bispecific antibody, and a therapeutic agent for cancer comprising the bispecific antibody, are also provided.SELECTED DRAWING: None